Marinomed Biotech AG | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Marinomed Biotech AG

BRIEF

published on 02/28/2025 at 10:25, 9 months 4 days ago

Marinomed Biotech Finalizes Carragelose Business Sale to Unither

Strategic Investment Carragelose Marinomed Unither Pharmaceuticals Biotech Sale
PRESS RELEASE

published on 02/28/2025 at 10:20, 9 months 4 days ago

Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals
Marinomed Biotech AG successfully completes the sale of Carragelose business to Unither Pharmaceuticals, marking a strategic decision. Deal includes upfront payment of EUR 5 million and transition service agreement

Strategic Decision Marinomed Biotech AG Sale Completion Unither Pharmaceuticals Carragelose Business
BRIEF

published on 01/31/2025 at 12:15, 10 months 4 days ago

Marinomed Biotech AG Announces Management Board Changes

CFO Resignation Marinomed Biotech AG Financial Restructuring Management Changes Marinosolv Platform
PRESS RELEASE

published on 01/31/2025 at 12:10, 10 months 4 days ago

Marinomed Biotech AG: Changes to the Management Board
Marinomed Biotech AG announces CFO resignation and appointment of interim finance manager. Successful completion of restructuring and securing financing by selling Carragelose business unit

Restructuring CFO Resignation Marinomed Biotech AG Carragelose Interim Finance Manager
BRIEF

published on 01/20/2025 at 07:50, 10 months 15 days ago

Marinomed Biotech AG Completes Restructuring Proceedings

Restructuring Insolvency Business Sale Marinomed Biotech Creditor Approval
PRESS RELEASE

published on 01/20/2025 at 07:45, 10 months 15 days ago

Marinomed Biotech AG: Restructuring proceedings successfully completed
Marinomed Biotech AG successfully completes restructuring proceedings, fulfilling plan to be funded by Carragelose business sale and Marinosolv asset commercialization

Commercialization Marinomed Biotech AG Carragelose Restructuring Proceedings Marinosolv Asset
BRIEF

published on 12/19/2024 at 12:44, 11 months 16 days ago

Marinomed Biotech AG Approves Sale of Carragelose Division

Board Changes Strategic Focus Marinomed Biotech AG Sale Approval Carragelose Division
PRESS RELEASE

published on 12/19/2024 at 12:39, 11 months 16 days ago

Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
Marinomed Biotech AG's extraordinary general meeting approves sale of Carragelose division, ensuring implementation of restructuring plan. Dr. Karl Mahler elected to the Supervisory Board

Supervisory Board Marinomed Biotech AG Restructuring Plan Sale Approval Carragelose Division
BRIEF

published on 12/17/2024 at 13:05, 11 months 18 days ago

Marinomed Biotech AG Achieves Restructuring Milestone

Convertible Bond Carragelose Sale Marinomed Restructuring EIB Agreement Biotech Finance
PRESS RELEASE

published on 12/17/2024 at 13:00, 11 months 18 days ago

Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved
Marinomed Biotech AG successfully meets requirements for restructuring with funds deposited for cash quota & legal costs. European Investment Bank standstill agreement secured for completion. Sale of Carragelose business to ensure sustainable existence

Restructuring Marinomed Biotech AG Financial Stability Carragelose Sale EIB Agreement

Accesswire

Published on 12/05/2025 at 02:35, 4 hours 36 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 4 hours 41 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 6 hours 11 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 8 hours 6 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 8 hours 11 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 07:00, 11 minutes ago

Swiss Re targets a net income of USD 4.5 billion in 2026; refreshed strategy to strengthen core business
Published on 12/05/2025 at 03:30, 3 hours 40 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 7 hours 20 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 10 hours 45 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 10 hours 56 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025

Les Echos

Published on 12/04/2025 at 18:00, 13 hours 11 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 13 hours 26 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 13 hours 27 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 13 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE